貝尼磷布韋
外觀
臨床資料 | |
---|---|
其他名稱 | AT-527、AT-511 |
法律規範狀態 | |
法律規範 |
|
識別資訊 | |
| |
CAS號 | 1998705-64-8( 2241337-84-6 (hemisulfate)) |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
化學資訊 | |
化學式 | C24H33FN7O7P |
摩爾質量 | 581.54 g·mol−1 |
3D模型(JSmol) | |
| |
|
貝尼磷布韋(INN:bemnifosbuvir;開發代號:AT-527、RO7496998)是一種抗病毒藥物,由Atea製藥發明並授權羅氏進行臨床開發。它也是一種新型核苷酸類似物前藥,最初開發用於治療丙型肝炎。[1][2]貝尼磷布韋可充當RNA聚合酶抑制劑,從而干擾病毒複製。因此,它已被研究用於治療冠狀病毒疾病,例如SARS-CoV-2引起的疾病。[3]該藥物在早期臨床試驗中展現出良好的結果,但在後期卻出現了不一致的結果。[4][5]貝尼磷布韋的III期研究因為未能達到緩解症狀的主要終點,也沒有降低病毒載量,所以提前結束了。然而,該藥物的耐受性良好,相對住院風險降低了71%。[6]
參見
[編輯]參考資料
[編輯]- ^ Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrobial Agents and Chemotherapy. September 2019, 63 (12). PMC 6879261 . PMID 31570394. doi:10.1128/AAC.01201-19.
- ^ Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi JP. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLOS ONE. 2020, 15 (1): e0227104. Bibcode:2020PLoSO..1527104G. PMC 6949113 . PMID 31914458. doi:10.1371/journal.pone.0227104 .
- ^ Good SS, Westover J, Jung KH, Zhou XJ, Moussa A, La Colla P, et al. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrobial Agents and Chemotherapy. March 2021, 65 (4). PMC 8097421 . PMID 33558299. doi:10.1128/AAC.02479-20.
- ^ Lowe D. AT-527 Fails a Phase II. In the Pipeline. Science.org. 19 October 2021 [2024-06-05]. (原始內容存檔於2021-10-25). 溫哥華格式錯誤 (幫助)
- ^ Fidler B, Gardner J. Atea, Roche change plans for oral COVID-19 drug after trial setback.. Biopharmadive.com. 19 October 2021 [2024-06-05]. (原始內容存檔於2021-11-17).
- ^ Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N, Ishak L, Zrinscak B, Belanger B, Granier C, Lin K, C Hurt A, Zhou XJ, Wildum S, Hammond J. Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY). Future Virology. November 2023, 18 (13). PMC 10621114 . PMID 37928891. doi:10.2217/fvl-2023-0115.